The nation’s largest veterans organization is throwing its full legislative weight behind expanding access to psychedelic medicine. At its recent national convention, the American Legion—representing more than 1.2 million service members and military veterans—formally adopted a resolution endorsing the Veterans Health Administration Novel Therapeutics Preparedness Act. The proposed congressional legislation aims to lay the groundwork for integrating breakthrough therapies, including substances like psilocybin and MDMA, into the Department of Veterans Affairs healthcare system to combat treatment-resistant mental health conditions.
The endorsement comes amid growing recognition that conventional psychiatric treatments often fall short for combat veterans. In its resolution, the Legion pointed out that standard therapies and prescription antidepressants fail to produce lasting remission for a majority of veterans living with post-traumatic stress disorder, while carrying high dropout rates. In contrast, emerging clinical trials using psychedelic-assisted therapy have demonstrated significant symptom relief and high remission rates for conditions like severe PTSD, major depression, and traumatic brain injury.
Under the bill, the VA would establish a dedicated Office of Novel Therapeutics alongside regional Centers of Excellence to build the clinical infrastructure, governance, and specialized workforce necessary to administer these intensive therapies safely. Rather than waiting years after regulatory breakthroughs occur, the measure directs the agency to actively prepare its facilities and evaluate interim access pathways while federal agencies like the FDA and DEA assess drug scheduling and safety data. Legion advocates emphasized that establishing this federal framework now ensures veterans will not face bureaucratic delays once these promising treatments gain regulatory approval.
Dabbin-Dad Newsroom
